NCT05716724 - O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

July 9, 2023

Study Completion Date

July 9, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.

Trial Locations (20)

4184

Thumbay Hospital Ajman, Ajman

9115

Dubai Diabetes Center, Dubai

11643

Dr. Sulaiman Al Habib Medical Group- Olaya, Riyadh

12343

Habib Medical Group, Riyadh

12474

Al Hammadi, Riyadh

12987

Dr. Sulaiman Al Habib Medical Group- Swedi, Riyadh

14963

Dallah Hospital_Riyadh, Riyadh

22077

New Mowasat Hospital, As Sālimīyah

22141

Almoosa Specialist Hospital, Ihsaa

23521

Saudi German Hospital, Jeddah

34234

Mouwasat Hospital Khobar, Khobar

500001

Dubai Hospital, Dubai

060008

KOC Hospital, Al Ahmadi

020000

Al Seef Hospital, As Sālimīyah

Glycemia Clinic, As Sālimīyah

053700

New Mowasat Clinics, Mangaf

Unknown

Al Garhoud Private Hospital, Dubai

Medcare Hospital, Dubai

NMC Specialty Hospital Dubai, Dubai

Oriana Hospital Sharjah, Sharjah city